Claes Karlsson

1.4k total citations
19 papers, 399 citations indexed

About

Claes Karlsson is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Claes Karlsson has authored 19 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 9 papers in Immunology. Recurrent topics in Claes Karlsson's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Claes Karlsson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Claes Karlsson collaborates with scholars based in Sweden, United Kingdom and Iran. Claes Karlsson's co-authors include Jeanette Lundin, Anders Österborg, Eva Kimby, Lotta Hansson, Håkan Mellstedt, Fredrik Celsing, Anders Österborg, Anna Porwit‐MacDonald, Eva Rossmann and Peter Edman and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Claes Karlsson

18 papers receiving 394 citations

Peers

Claes Karlsson
Thérèse Aurran‐Schleinitz France
Maria Luigia Vigliotti Italy
A. Lakhani United Kingdom
Cassandra M. Hirsch United States
Massimo Pini Italy
M. Hidajat Belgium
RJ Lukes United States
Nicolò Compagno Switzerland
P Travade France
Rina Kansal United States
Thérèse Aurran‐Schleinitz France
Claes Karlsson
Citations per year, relative to Claes Karlsson Claes Karlsson (= 1×) peers Thérèse Aurran‐Schleinitz

Countries citing papers authored by Claes Karlsson

Since Specialization
Citations

This map shows the geographic impact of Claes Karlsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claes Karlsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claes Karlsson more than expected).

Fields of papers citing papers by Claes Karlsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claes Karlsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claes Karlsson. The network helps show where Claes Karlsson may publish in the future.

Co-authorship network of co-authors of Claes Karlsson

This figure shows the co-authorship network connecting the top 25 collaborators of Claes Karlsson. A scholar is included among the top collaborators of Claes Karlsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claes Karlsson. Claes Karlsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Masucci, Michele, Ingemar Ernberg, Claes Karlsson, & Lennart Blomqvist. (2024). Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine. Preprints.org. 5 indexed citations
2.
Masucci, Michele, Claes Karlsson, Lennart Blomqvist, & Ingemar Ernberg. (2024). Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine. Journal of Personalized Medicine. 14(6). 561–561. 6 indexed citations
3.
Johansson, Hemming, Jenny Klintman, Eva Kimby, et al.. (2018). First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 104(4). 797–804. 28 indexed citations
4.
5.
Andersson, Per‐Ola, Karin Karlsson, Claes Karlsson, et al.. (2017). Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program. Blood. 130. 5353. 2 indexed citations
6.
7.
8.
9.
Hansson, Lotta, et al.. (2013). Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & lymphoma. 55(8). 1774–1780. 8 indexed citations
10.
11.
Österborg, Anders, Claes Karlsson, & Jeanette Lundin. (2008). Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports. 4(1). 47–53. 21 indexed citations
12.
Karlsson, Claes, Jeanette Lundin, Eva Kimby, et al.. (2008). Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144(1). 78–85. 23 indexed citations
13.
Karlsson, Claes, Lotta Hansson, Fredrik Celsing, & Jeanette Lundin. (2007). Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 21(3). 511–514. 47 indexed citations
14.
Österborg, Anders, Claes Karlsson, Jeanette Lundin, Eva Kimby, & Håkan Mellstedt. (2006). Strategies in the Management of Alemtuzumab-Related Side Effects. Seminars in Oncology. 33(2 Suppl 5). 29–35. 43 indexed citations
15.
Jeddi‐Tehrani, Mahmood, Claes Karlsson, Jeanette Lundin, et al.. (2006). Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia. British Journal of Haematology. 135(4). 475–485. 17 indexed citations
16.
Lundin, Jeanette, et al.. (2006). Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.. Medical Oncology. 23(3). 137–9. 9 indexed citations
17.
Lundin, Jeanette, Claes Karlsson, & Fredrik Celsing. (2006). Alemtuzumab Therapy for Severe Autoimmune Hemolysis in a Patient with B-Cell Chronic Lymphocytic Leukemia. Medical Oncology. 23(1). 137–140. 7 indexed citations
18.
Lundin, Jeanette, Fredrik Celsing, Claes Karlsson, & Anders Österborg. (2005). Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).. Blood. 106(11). 2967–2967. 3 indexed citations
19.
Lundin, Jeanette, Anna Porwit‐MacDonald, Eva Rossmann, et al.. (2004). Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 18(3). 484–490. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thérèse Aurran‐Schleinitz Breakdown of academic impact, for papers by Maria Luigia Vigliotti Breakdown of academic impact, for papers by A. Lakhani Breakdown of academic impact, for papers by Cassandra M. Hirsch Breakdown of academic impact, for papers by Massimo Pini Breakdown of academic impact, for papers by M. Hidajat Breakdown of academic impact, for papers by RJ Lukes Breakdown of academic impact, for papers by Nicolò Compagno Breakdown of academic impact, for papers by P Travade Breakdown of academic impact, for papers by Rina Kansal
Rankless by CCL
2026